ACS Clinical Research Program
Modified FOLFIRINOX is superior to gemcitabine as adjuvant therapy for resected pancreatic cancer: The PRODIGE 24/CCTG PA6 Trial(0)
The study design and findings of the PRODIGE 24/CCTG PA6 Trial are outlined, which showed improved survival with modified FOLFIRINOX for resected pancreatic cancer patients.
The ALCHEMIST CHEMO-IO is a trial for patients with early-stage non-small cell lung cancer (NSCLC) with the potential to change the way patients with resected NSCLC are treated.
A summary of some of the research that evaluates the role of axillary reverse mapping in cancer patients.
Describes the traditional management of desmoid tumors as well as new approaches, including radiation therapy for locally aggressive tumors.
Putting the needle before the knife: Minimally invasive approaches to diagnostic lymph node biopsy in melanoma
Minimally invasive approaches to diagnostic lymph node biopsy in melanoma are recommended as a first step in value-based care for the patient.
More in this category
- Gastric cancer: Recent updates in surgical and multimodality therapy
- Organ preservation in rectal adenocarcinoma: The OPRA Trial
- Opportunities at Clinical Congress 2019 to increase surgeon participation in clinical research
- Defining the optimal treatment of locally advanced gastric cancer
- Preoperative smoking intervention techniques improve outcomes for lung cancer patients
- Atezolizumab in the adjuvant treatment of stage III colon cancer: Can PD-L1 inhibition improve survival?
- Cytoreduction with or without HIPEC: Where do we go from here?
- Robotic surgery for hepatic neoplasms: Where does it fit in the minimally invasive surgery landscape?
- Surveillance testing for colorectal cancer: New evidence supports a change in guidelines
- Colorectal cancer in adults younger than 50 years old
- The evolving clinical management of sentinel node-positive melanoma: The impact of MSLT-II on clinical practice
- Liquid biopsies in cancer clinical trials
- Geriatric assessment and frailty in older cancer patients
- Immunotherapy in solid tumors
- Duration of adjuvant therapy for stage III colon cancer: No longer one size fits all